Victoria Socha

DocwireNews

One of the most common complications of chronic kidney disease (CKD) is renal anemia. The noninterventional, multicenter, pragmatic NAVIGO trial was designed to assess the effectiveness of methoxy polyethylene glycol-epoetin beta for the treatment of CKD-associated anemia in patients receiving dialysis in clinical practice in Poland. Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator (CERA). Michal Nowicki, MD, and colleagues reported results of the trial.A total of 247 patients receiving chronic intermitted dialysis in 26 centers in Poland were enrolled in the real-world study. Of those, 224 were receiving hemodialysis and 23 were receiving peritoneal dialysis. Eligible patients had CKD-associated symptomatic anemia, were not being treated with an erythropoietin stimulating agent, and had balanced iron stores. Over a period of 12 months, the researchers collected data on hemoglobin concentration and dosage, the route of administration and dosing scheme of CERA, dialysis adequacy, adverse events, iron therapy, and blood transfusion.During treatment, a hemoglobin concentration of &ge;10 g/dL was observed in 90.9% of study participants receiving hemodialysis and 96.0% of participants receiving peritoneal dialysis. At baseline, 7.8% of the overall cohort had a hemoglobin concentration of 10 to 12 g/dL. The percentage increased to 63.3% after 12 months.The median time for maintenance of hemoglobin concentration within the 10 to 12 g/dL range was 115.2 days. After 7 months of treatment, a maximum 24.1% of patients in the hemodialysis group had a hemoglobin concentration &ge;12 g/dL and maximum of 31.8% of the patients in the peritoneal dialysis group met that criterion. The median time between treatment initiation and the first hemoglobin concentration of &gt;10 g/dL was 42.0 days. CERA was well tolerated.In summary, the authors said, &ldquo;CERA corrects CKD-associated anemia in dialysis patients, and maintains hemoglobin levels within the recommended target range. The study also confirmed the acceptable safety profile of the drug.&rdquo;Study identifier at ClinicalTrials.gov: NCT01690455Source: <a href="https://karger.com/nef/article/doi/10.1159/000534070/862942/Continuous-erythropoietin-receptor-activator-for?searchresult=1" target="_blank" rel="noopener">Nephron</a>

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Treating CKD-Associated Anemia

Anemia and Kidney Disease

The median time for maintenance of hemoglobin concentration within the 10 to 12 g/dL range was 115.2 days.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe